Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Primary result · Mean glucose level (CGM)Result — go to the resultReduction in mean glucose 2.3 mmol/L 95% CI 1.3–3.3Authors' conclusion
Empagliflozin used for 4 weeks in adjunction with other glucose-lowering treatments markedly improved glycemia compared with placebo in individuals with HNF1A-MODY without significantly increasing risk of hypoglycemia or unexpected adverse effects.
Study context
- Population
- Adults with HNF1A-MODY treated with at least one glucose-lowering drug18 completed
- Participants
- 19 adults
- Comparison
- Empagliflozin 25 mg add-on vs placebo
- Primary endpoint
- Mean glucose concentration assessed by 10 days of continuous glucose monitoring (CGM)
Methodological detailsdouble-blind, placebo-controlled, crossover
- Double-blind
- Placebo-controlled
- Crossover
Primary result
Mean glucose level (CGM) · 4 weeks
Reduction in mean glucose
2.3 mmol/L
95% CI 1.3–3.3
P = 0.0001
As reported in the abstract
- Empagliflozin lowered the mean glucose level vs placebo
- 2.3 mmol/L
Further findings
- No significant differences in hypoglycemic outcomes
Safety
- Severe adverse events or study drug discontinuations attributable to empagliflozin
- 0
- Adverse events generally mild and transient
Original publication
Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →